Fed. Circ. Appears Split On Novartis' MS Drug Patent
The Federal Circuit wasn't in agreement Thursday about the strength of one of the patents covering Novartis' blockbuster multiple sclerosis drug Gilenya, with two of the panel judges at times using...To view the full article, register now.
Already a subscriber? Click here to view full article